Institute of Cancer Studies, Christie Hospital and University of Manchester, Wilmslow Road, Withington, Manchester, UK.
Center for Cancer Research, National Cancer Institute, Bethesda MD, USA.
Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21.
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.
上皮性卵巢癌是妇科癌症相关死亡的最常见原因。这种疾病通常发生在绝经后妇女中,有几个月的腹痛和腹胀。大多数妇女患有晚期疾病(国际妇产科联合会[FIGO]III 期),其标准治疗仍然是手术和铂类细胞毒性化疗。尽管这种治疗对大多数早期疾病患者是有效的,但大多数晚期疾病患者将经历多次复发性疾病,无疾病间隔时间逐渐缩短。这些疾病最终导致耐药性,并最终导致肠梗阻,这是最常见的死亡原因。对于那些疾病继续对铂类药物有反应的女性,疾病通常可以控制 5 年或更长时间。靶向治疗,如抗血管生成药物或聚(ADP-核糖)聚合酶抑制剂,为提高生存率提供了潜力。旨在更早和更可治愈阶段检测疾病的筛查的疗效仍未得到证实,预计 2015 年将得出关键结果。